RSV INFECTION

This early-stage study tested two experimental RSV vaccines given as nose drops in 60 children. Some children already had RSV antibodies (ages 1-5) and some did not (ages 6 months-2 years). The main goals were to check safety and whether the vaccines triggered an immune response.

This early-stage trial tested a new vaccine designed to protect against both RSV and hMPV, two common respiratory viruses. 385 healthy adults aged 60 to 75 received a single injection of different doses. The main goals were to check safety and measure the immune response. Results…

This study tested an experimental oral drug called EDP-323 in 142 healthy adults who were deliberately infected with RSV. The goal was to see if the drug is safe and can reduce the amount of virus in the nose compared to a placebo. Results will help determine if EDP-323 could be …

This study tested two new rapid tests that use a single nose swab to detect COVID-19, influenza A/B, and RSV. Researchers checked how accurate the tests are compared to standard lab methods and whether healthcare workers find them easy to use. The study involved 589 people with s…

This study collected nasal swabs, throat swabs, and saliva samples from 79 people with symptoms of flu, RSV, or COVID-19. The samples were used to help evaluate a point-of-care device called LumiraDx, which aims to quickly and accurately detect these viruses. The study focused on…

This study tested a new medicine called clesrovimab in over 1,000 infants and children at high risk for severe RSV disease. The goal was to see if it is safe and works as well as or better than the current standard treatment, palivizumab. Participants received either clesrovimab …

This study looked at how the immune system of older adults (ages 60-75) responds to a controlled infection with respiratory syncytial virus (RSV). Researchers gave 28 healthy volunteers a weakened form of the virus via nasal drops and monitored their symptoms and immune reactions…